Hemoperfusion With Efferon CT for the Treatment of Patients With Severe Psoriasis

Korábbi kezelés

• patients on genetically engineered biological therapy (GEBT) for psoriasis.

Más betegség

• patients with other forms of psoriasis (e.g. psoriatic erythroderma, pustular psoriasis, scale psoriasis, psoriatic arthritis) or other skin conditions (e.g. eczema).
• patients with HIV infection, syphilis, acute infectious diseases, tuberculosis.
• patients with oncological diseases.
• patients with chronic diseases in the stage of decompensation.
• patients with thrombosis and recurrent thromboembolism, thrombophlebitis.
• mental condition in which the subject is unable to understand the nature, purpose and possible implications of this research.
• history of allergy, hypersensitivity to components of the extracorporeal circuit.

Életkor

• age of patients younger than 18 years and older than 70 years.

Egyéb

• patients with mild forms of psoriasis.
• female patients who are pregnant or breastfeeding.
• in the opinion of the investigator, inability of the subject to participate in this study for any other reason.
• inability or unwillingness to undergo all follow-up procedures until the end of the study and/or unwillingness to allow access to their medical records in accordance with national regulatory requirements at the time of consent.
• Charlson Index score greater than 6.

• ability to provide written informed consent and willingness and ability to comply with all requirements of the clinical trial design.
• 18 to 70 years of age.
• moderate to severe psoriasis (plaque psoriasis without psoriatic arthritis) with a disease duration of at least 6 months.
• should be receiving standard psoriasis therapy according to clinical recommendations (topical therapy, systemic therapy, phototherapy).
• Psoriasis Area and Severity Index (PASI) score ≥10,
• Body surface area (BSA) affected by psoriasis ≥10%,
• Dermatology Life Quality Index (DLQI) score >10 points,
• physician's global assessment of psoriasis severity using the static Physician Global Assessment (sPGA) ≥3 points,
• Dermatological Disease Severity Index (DIDS) score ≥2.
• for female patients: postmenopausal or have a negative pregnancy test (urinalysis) prior to enrolment. If urinalysis does not confirm absence of pregnancy, an appropriate serum analysis should be performed. The subject's pregnancy test must be negative to be eligible for inclusion in the study.